Dr. Katherine Scilla, MD
Claim this profileUniversity of Maryland/Greenebaum Cancer Center
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
11 reported clinical trials
20 drugs studied
Area of expertise
1Lung Cancer
Stage III
Stage IV
Stage II
2Non-Small Cell Lung Cancer
Stage III
Stage II
Stage I
Affiliated Hospitals
Clinical Trials Katherine Scilla, MD is currently running
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Chemo-Immunotherapy + Durvalumab + Ceralasertib
for Small Cell Lung Cancer
The primary objective of this single arm study is to estimate the progression free survival of previously-untreated patients with extensive stage small cell lung cancer. Patients will receive initial chemo-immunotherapy followed by maintenance therapy with durvalumab and oral ceralasertib.
Recruiting1 award Phase 215 criteria
More about Katherine Scilla, MD
Clinical Trial Related11 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 7 Active Clinical TrialsTreatments Katherine Scilla, MD has experience with
- Carboplatin
- Durvalumab
- Biospecimen Collection
- Pembrolizumab
- Repotrectinib (TPX-0005)
- Nivolumab
Breakdown of trials Katherine Scilla, MD has run
Lung Cancer
Non-Small Cell Lung Cancer
Mesothelioma
Neuroendocrine Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Katherine Scilla, MD specialize in?
Katherine Scilla, MD focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage III patients, or patients who are Stage IV.
Is Katherine Scilla, MD currently recruiting for clinical trials?
Yes, Katherine Scilla, MD is currently recruiting for 7 clinical trials in Baltimore Maryland. If you're interested in participating, you should apply.
Are there any treatments that Katherine Scilla, MD has studied deeply?
Yes, Katherine Scilla, MD has studied treatments such as Carboplatin, Durvalumab, Biospecimen Collection.
What is the best way to schedule an appointment with Katherine Scilla, MD?
Apply for one of the trials that Katherine Scilla, MD is conducting.
What is the office address of Katherine Scilla, MD?
The office of Katherine Scilla, MD is located at: University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland 21201 United States. This is the address for their practice at the University of Maryland/Greenebaum Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.